 |
 |
 |
 |
 |
 |
 |
 |
Email
Print-Friendly
SubscribeHIV Care Today
By Paul E. Sax, M.D.
May 10, 2012
As I've mentioned before, I have no doubt whatsoever that TDF/FTC works for PrEP, provided the person actually takes the med. And while it's not yet approved for this indication, nothing has stopped clinicians from prescribing it already. There's even a CDC "Guidance" on the practice that's now over a year old. Remember, we give TDF/FTC all the time for post-exposure prophylaxis.
By Paul E. Sax, M.D.
April 30, 2012
I'm currently on the inpatient consult service and just saw a guy who fits the typical profile of many hospitalized HIV patients in 2012:
By Paul E. Sax, M.D.
April 23, 2012
The excitement about "treatment as prevention," and the results of Study 052, have led to many patients asking the question (if not in these words, than using others with a less medical slant), "So if I'm on treatment and doing well, just what is the risk of my transmitting HIV to others?"
By Paul E. Sax, M.D.
April 10, 2012
Over in Journal Watch AIDS Clinical Care, Abbie Zuger has written a fascinating perspective on the recent enthusiasm for universal HIV treatment.
Her take? Let's just say she doesn't share the enthusiasm of public health officials and members of guidelines committees. Well, that's a huge understatement.
By Paul E. Sax, M.D.
March 27, 2012
From the key "What's New in the Guidelines" section of today's Department of Health and Human Services update:
ART is recommended for all HIV-infected individuals. The strength of this recommendation varies on the basis of pretreatment CD4 cell count.
By David Fawcett, Ph.D., L.C.S.W.
March 26, 2012
Several attendees drove fifteen hours from St. Louis. Others came by caravan from Atlanta. In the hotel lobby there were happy reunions of friends who hadn't seen each other since last year. Overall nearly four hundred and fifty people made their way from 22 states to the white sandy beaches of the Florida panhandle in early March. It was spring break, but their purpose was much more a matter of life and death. They were gathering for Positive Living 15, the largest conference in the nation specifically for people living with HIV.
By Paul Sax, M.D.
March 22, 2012
Screening for anal cancer in men who have sex with men (MSM) -- with pap smears, high resolution anoscopy, with whatever test -- is quite the quagmire.
By Paul Sax, M.D.
March 15, 2012
Some highly subjective highlights -- a Really Rapid Review™ -- from this year's Number One Greatest Super Scientific HIV Conference, the 19th Conference on Retroviruses and Opportunistic Infections (CROI), which ended last week in Seattle:
By Paul Sax, M.D.
February 26, 2012
You know that tenofovir, emtricitabine, and efavirenz HIV regimen? The one that's universally listed as one of the "Preferred," or "Recommended" or "First-line" options in all HIV treatment guidelines in the universe? And the regimen that is easily the most widely used in the USA today? Well, here's a surprising review from Cochrane Summaries, entitled "Effectiveness and safety of first-line tenofovir + emtricitabine + efavirenz for patients with HIV" ...
By Paul Sax, M.D.
February 23, 2012
The news that hepatitis C (HCV) has passed HIV as a cause of death in the United States got quite a bit of attention when it was first presented last year at ICAAC -- and no doubt the published paper, in this week's Annals of Internal Medicine, will also cause a stir. In fact, I boldly predict that going forward, (approximately) 94.2% of HCV-related research grants, journal articles, and lay press articles will cite this paper, making it (for now) the "Palella NEJM 1998" of HCV.
Get email notifications every time HIV Care Today is updated.
This article was provided by TheBodyPRO.com. HIV Care Today is a multi-author blog featuring people on the frontlines of HIV treatment, prevention and patient/client care. This blog serves as a platform for these health care professionals to discuss the everyday challenges of their jobs, recent developments in their fields and issues relevant to the evolution of HIV/AIDS care.
Subscribe to This Blog:
 | By RSS  |
 | |
Bloggers and Contributors:
- David Fawcett, Ph.D., L.C.S.W.
- Lisa Fitzpatrick, M.D., M.P.H.
- Bethsheba Johnson, G.N.P.-B.C., A.A.H.I.V.S.
- Paul E. Sax, M.D.
- Nelson Vergel, B.S.Ch.E., M.B.A.
Recent Posts:
April 30, 2012 - Do We Really Need Primary Prophylaxis for OIs Anymore?
April 23, 2012 - An Answer to a Commonly Asked Question: Is Treatment 100% Effective in Preventing HIV Transmission?
April 10, 2012 - A Skeptical Look at "Test and Treat"
March 27, 2012 - Latest Guidelines Recommend HIV Treatment for All
A Brief Disclaimer:
The opinions expressed by TheBodyPRO.com's bloggers are entirely their own, and do not necessarily reflect the views of TheBodyPRO.com itself.
TheBodyPRO.com: About TheBodyPRO.com | Contact TheBodyPRO.com | Content Policy | Advertise With Us
Remedy Health Media: About Remedy Health Media | Contact Remedy Health Media | Terms of Use | Privacy Policy
TheBodyPRO.com is a service of Remedy Health Media, LLC, 250 West 57th Street, New York, NY 10107. TheBodyPRO.com and its logos are trademarks of Remedy Health Media, LLC, and its subsidiaries, which owns the copyright of TheBodyPRO.com's homepage, topic pages, page designs and HTML code. General Disclaimer: TheBodyPRO.com is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through TheBodyPRO.com should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.
